Dutch Health Ingredients company, NUTRILEADS BV, announces the closing of a Series B financing round of 6.5 m€, led by ICOS CAPITAL together with GOEIE-GRUTTEN and existing shareholders DSM VENTURING, OOST NL, SHIFT INVEST and THUJA.
NutriLeads, established in 2012, develops innovative natural food ingredients with clinically proven health benefits for application in dietary supplements and functional foods. Its proprietary lead ingredient, XtramuneTM, is a unique carrot-derived fibre supporting immune function and resistance to respiratory infections. This series B funding round marks a new phase for the company. Together with global partners in the food and supplement industry, NutriLeads will be driving XtramuneTM towards commercialization in 2021. In addition, two other ingredients from its portfolio, targeting gut health and metabolic health, will be progressed to proof of concept in humans
